Natural Selections

Seven wonder drugs that do grow on trees.

Illustration: Bettmann/Corbis

For indispensable reporting on the coronavirus crisis and more, subscribe to Mother Jones' newsletters.


As much as three-quarters of the drugs approved to treat infectious disease and cancer over the past 25 years originated with chemicals or compounds first found in nature. Which means that last acre of rainforest or ocean floor might contain ever more promising cures. A few notable pharmaceuticals that got their start outside the laboratory:

ASPIRIN In the fifth century BC, Hippocrates noted willow bark’s ability to fight fevers and pain. A chemical found in the bark became the key ingredient of aspirin, patented in 1900.

QUININE Indigenous Peruvians used the bark of the cinchona tree to cure fevers. European scientists isolated its antimalarial ingredient in the early 19th century.

LOVASTATIN This chemical, found in the fungus Aspergillus terreus and oyster mushrooms, reduces LDL “bad” cholesterol. In 1987 it became the first FDA-approved statin.

CALANOLIDE A In the late 1980s, a rare tree from Borneo was found to have antiretroviral properties. Still in trials, the resulting drug has shown promise in combating HIV.

TAXOL Tumor-fighting compound derived from the bark of the Pacific yew, introduced as a cancer drug in 1993. It’s since been found in some mushrooms and mycelia.

YONDELIS A cancer drug modeled after an agent discovered in a Caribbean sea squirt. Currently available only in the EU.

PRIALT In 2004, Elan Pharmaceuticals unveiled this drug for treating chronic pain, made from synthetic sea-snail venom. The drug’s logo is a snail shell.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate